Chemotherapy-induced peripheral neuropathy

Journal of Neurology

Volumn 249, Issue 1, 2002, Pages 9-17

  Quasthoff, Stefan ^a   Hartung, Hans Peter ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cisplatin; Suramin; Taxol; Vincristine

Indexed keywords

ALCOHOL; AMIFOSTINE; CALCIUM ION; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CORTICOTROPIN; DOCETAXEL; GABAPENTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; GLUTATHIONE; MAGNESIUM; NERVE GROWTH FACTOR; NEUROTROPIC AGENT; NIMODIPINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROCARBAZINE; SOMATOMEDIN; SURAMIN; THIOCTIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; VINCRISTINE;

AUTONOMIC NEUROPATHY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONVALESCENCE; DIABETES MELLITUS; DISEASE COURSE; DRUG WITHDRAWAL; HEREDITY; HUMAN; MOTOR NEUROPATHY; NERVE REGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PAIN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY;

EID: 0036158822     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007853     Document Type: Review

References (63)

1. The chemotherapeutic oxali-platin alters voltage-gated Na(+) channel kinetics on rat sensory neurons
2. Neurotrophic factors in the treatment of neurotoxicity: An overview
3. Nerve growth factor prevents experimental cisplatin neuropathy
4. Strategies offering protection from the toxic effects of anticancer treatments with a focus on chemoprotective agents
5. Fulminant demyelinating neuropathy mimicking cerebral death
6. Potent analgesic effects of GDNF in neuropathic pain states
7. Vocal fold palsy following vinca alkaloid treatment
8. Clinical status and optimal use of amifostine
9. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial
10. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin
11. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin
12. Carboplatin toxic effects on the peripheral nervous system of the rat
13. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol
14. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electro-physiological studies
15. A prospective study of suramin-induced peripheral neuropathy
16. Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice
17. Dosing considerations with amifostine: A review of the literature and clinical experience
18. Pharmacokinetics and safety profile of oxaliplatin
19. ACTH/MSH like peptides in the treatment of cisplatin neuropathy
20. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A
21. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity
22. Oxalinplatin-induced neuropathy differs from cisplatin and taxol neuropathy due to acute alteration of voltage-gated sodium channels in sensory neurons
23. Progressive paraesthesias after cessation of therapy with very high-dose cisplatin
24. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma
25. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: In vitro study of adult rat sympathetic ganglion explants
26. Peripheral neurotoxicity induced by docetaxel
27. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere)
28. Solution structure of a cisplatin-induced DNA interstrand cross-link
29. Vincristine neurotoxicity. Pathophysiology and management
30. Cisplatin neuropathy: Clinical course and neurophysiological findings
31. Prevention of peripheral sensory neuropathy (PSN) by Carbamazepine in patients with advanced colorectal cancers (ACRC) treated with oaxliplatin. A pilot study
32. Differences in the sensitivity to purinergic stimulation of myelinating and non-myelinating Schwann cells in peripheral human and rat nerve
33. Reporting results of cancer treatment
34. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
35. Peripheral neuropathy secondary to docetaxel (Taxotere)
36. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials
37. Toxicity and response criteria of the Eastern Cooperative Oncology Group
38. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer
39. Long-term effects of vincristine on the peripheral nervous system
40. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy
41. Grading of chemotherapy-induced peripheral neuropathy
42. Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma
43. Paclitaxel-induced neuropathy
44. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel
45. Taxol-cisplatin neuropathy caused by membrane leak and axonal depolarization: An in vivo and in vitro study
46. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer
47. Inhibition of cell division in Escherichia coli by electrolysis products from platinum electrodes
48. Clinical toxicities encountered with paclitaxel (Taxol)
49. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings
50. Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: A clinical phase I study
51. An electrophysiological investigation of the effects of cisplatin and the protective actions of dexamethasone on cultured dorsal root ganglion neurones from neonatal rats
52. Carboplatin and paclitaxel in non-small cell lung cancer: The role of amifostine
53. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps
54. Calcium in suramin-induced rat sensory neuron toxicity in vitro
55. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat
56. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck
57. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
58. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin
59. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer
60. Neurotoxic effects of cisplatin therapy
61. P2 purinoceptor-mediated intracellular Ca2+ transients in human sural nerve
62. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity
63. Oxaliplatin: A review of its use in the management of metastatic colorectal cancer